Abbott Laboratories (NYSE:ABT) announced it has entered into an agreement to purchase two companies to add to its Medical Device portfolio: IDEV Technologies, a peripheral play ($310 million) and OptiMedica, an ophthalmic device company ($250 million+$150 million milestone based payments).
Deal impact: IDEV Technologies & OptiMedica
Management expects to close both deals before the end of the year and have a neutral impact in 2013-2014 and accretive there after. No change to 2013 EPS guidance. Over time, Abbott Laboratories (NYSE:ABT) estimates each acquisition will turn into a several hundred million dollar revenue opportunity. RBC Capital believe these deals are...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
